Baranyi, Marcell
Molnár, Eszter
Hegedűs, Luca
Gábriel, Zsófia
Petényi, Flóra Gréta
Bordás, Fanni
Léner, Violetta
Ranđelović, Ivan
Cserepes, Mihály
Tóvári, József
Hegedűs, Balázs http://orcid.org/0000-0002-4341-4153
Tímár, József
Article History
Received: 1 June 2023
Revised: 10 January 2024
Accepted: 15 January 2024
First Online: 26 January 2024
Competing interests
: The authors declare that MB, EM, JTímár, JTóvári, IR and BH filed an international patent for the combinational treatment of <i>KRAS</i> inhibitors and farnesyl-transferase inhibitors of <i>KRAS</i> mutant cancers (patent number: PCT/HU2022/050077, priority date: 2021.11.02). Besides, MB, IR, VL acknowledge to be contracted employees and JTóvári to be chief scientific officer of Kineto Lab Ltd.
: PF97 and PF139 cells were established from malignant pleural effusion samples in cooperation with the West German Biobank Essen. The patients provided written informed consent and the experiments were approved by the Ethics Committee of the University Hospital Essen (#18-8208-BO). For in vivo experiments, 56 female SCID mice were obtained from KINETO Lab’s animal house (Budapest, Korányi str. 1, H-1121, Hungary, license number: PEI-001-1715-2/2015, 24/07/2015). All experiments were carried out following the Guidelines for Animal Experiments. Permission Number: PE/EA/401-7/2020, 23/04/2020. The animal experiment was performed according to the regulations and recommendations from directive 2010/63/EU of the European Parliament and the Council of the European Union on the protection of animals used for scientific purposes. The health status of the mice was assessed by the animal house staff of KINETO Lab.